Abstract Aim of the work: Monocytes are divided into three major subsets based on the expression of the cluster of differentiation CD14 and CD16. The aim of this work was to determine which of the CD16 + monocyte subpopulations is expanded in rheumatoid arthritis (RA) and its association with disease activity and interleukin-17 (IL17) levels. Patients and methods: Fifty-three RA patients and 20 controls were enrolled in this study. Flow cytometry was performed to detect monocyte subsets and IL17 was measured by ELISA. Disease activity score (DAS28) was assessed.
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Abstract Aim of the work: Monocytes are divided into three major subsets based on the expression of the cluster of differentiation CD14 and CD16. The aim of this work was to determine which of the CD16 + monocyte subpopulations is expanded in rheumatoid arthritis (RA) and its association with disease activity and interleukin-17 (IL17) levels. Patients and methods: Fifty-three RA patients and 20 controls were enrolled in this study. Flow cytometry was performed to detect monocyte subsets and IL17 was measured by ELISA. Disease activity score (DAS28) was assessed.
Results: CD14 ++ CD16 + monocyte percentage was significantly higher in long standing RA patients compared with early patients and controls (p < 0.01, p < 0.001 respectively). It was significantly higher in patients with RA disease activity and remission compared with the controls (p < 0.001, p < 0.01 respectively). It was not significantly associated with resistance to disease modifying antirheumatic drugs (DMARDs), C-reactive protein, rheumatoid factor and anti-CCP positivity (p > 0.05). It significantly correlated with IL17 (p < 0.002). CD14 + CD16 + monocyte percentage was not significantly correlated with any of the above parameters. IL17 level was significantly higher in patients with early and long standing RA compared to controls (p < 0.01, p < 0.001 respectively). IL17 was higher in RA patients with active disease compared to those in remission and controls (p < 0.01, p < 0.001 respectively). It was higher in RA patients resistant to DMARDs than in responding patients (p < 0.017). Conclusion: CD14 ++ CD16 + monocyte subpopulation was expanded in long standing RA and was correlated with IL17 levels indicating its potential pathogenic importance in RA and may represent an attractive target for future therapeutic interventions. 
Introduction
Accumulating evidence supports that cluster of differentiation CD4+CD25+ regulatory T cells play an essential role in controlling rheumatoid arthritis (RA) [1] . T helper-17 cells and interleukin (IL-17) play an important role in the pathogenesis of inflammatory and destructive pattern characteristic [2] . In a previous study, proteinase-activated receptor-2 expression on monocytes was remarkably high in active RA patients and consistent with a pathogenic role while its expression on CD3+ T-cells was not [3] . Cells of the monocyte/macrophage lineage play important roles in RA pathogenesis, the perpetuation of inflammation, and are potential targets for activation by immune complexes (ICs). Activated macrophages are the predominant infiltrating cells found in RA synovium, pannus and nodules [4, 5] . Macrophages play a role in phagocytosis, antigen presentation, antibody-dependant cell-mediated cytotoxicity and release of pro-inflammatory cytokines and tissue destructive mediators [6] . The migration of monocytes from blood to synovial tissue and their differentiation into macrophages may be an important step in disease pathogenesis [7] . Macrophages are the major source of pro-inflammatory cytokines in the inflamed RA joint including tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-8 and granulocyte-macrophage colonystimulating factor (GM-CSF) [4, 8] . FccRIIIa cross-linking has been specifically implicated in cytokine release from adherent human monocytes/macrophages [9, 10] . These cytokines are intimately involved in the disease process as demonstrated by the clinical efficacy of TNF or IL-1 blockade in RA [11, 12] .
Current knowledge defines three major monocyte subsets based on the expression patterns of CD16 and the receptor CD14: classical CD14 ++ CD16
À , intermediate CD14 ++
CD16
+ and non-classical CD14 + CD16 + monocytes [13] . These subsets differ essentially in their chemokine receptor expression, phagocytic activity and tissue distribution during inflammation or steady-state conditions [14] . Hence, monocyte subsets are differentially involved in the pathophysiology of inflammation, atherosclerosis and regeneration after injury [15] [16] [17] . In particular, the unique features of the intermediate in contrast to the nonclassical subset (both previously referred as CD16
+ monocytes) has become recently more evident and especially in cardiovascular disease this subset was shown to predict independently cardiovascular events at follow-up [18] [19] [20] . Thus, human monocyte subsets may represent a novel prognostic marker or therapeutic targets in clinical medicine.
The aim of the current study was to determine which of the two CD16 + monocyte subpopulations is expanded in RA and to investigate their possible association with disease activity and with IL17 levels.
Patients and methods
The present study was conducted on 53 RA patients attending out-patient clinic of Physical Medicine and Rehabilitation Department, Menoufia University Hospitals and 20 age and sex matched healthy controls. Patients were diagnosed as RA according to ACR/EULAR classification criteria 2010 [21] . Patients were classified according to RA disease duration into early (62 years, n = 19) and long standing RA (>2 years, n = 34). Each group was further subdivided according to the disease activity score in 28 joints (DAS28) [22] into 2 subgroups; activity and remission groups (early RA, activity n = 15, remission n = 4; long standing RA, activity n = 24, remission n = 10). The disease activity was further categorized as low, moderate and high [22] . This study was approved by the ethics committee of the Faculty of Medicine, Menoufia University. All patients provided signed informed consent to provide a blood sample and to review the medical record for research purposes.
Immunophenotyping of peripheral blood monocytes
100 ll peripheral blood mononuclear cells were incubated with 20 ll FITC-conjugated antihuman CD14 and 20 ll PE-conjugated antihuman CD16 (Immunostep, Spain) for 30 min at 4°C followed by red blood cells lysis and washing 
Statistical analysis
Analysis was performed with SPSS version 20 statistical software. Quantitative data were expressed as mean ± standard deviation. Two groups of non-normally distributed variables were tested by Mann-Whitney test. Comparisons of three groups of normally distributed variables by ANOVA test and non-normally distributed variables by Kruskal-Wallis test were made. Post hoc test was used after ANOVA (F test) or Kruskal-Wallis test to show any significant difference between the individual groups. Qualitative data were expressed as number and percentage (n and %) and analyzed by Chi-square test. Pearson correlation was used for normally distributed while Spearman correlation was used for non-normally distributed quantitative variables. p value < 0.05 was considered statistically significant.
Results
Fifty-three RA patients with a mean age of 44 ± 11.2 years and 20 age and sex matched healthy controls were included in this analysis. The mean disease duration was 7 ± 7.4 years. The demographic and laboratory data of the patients and control and disease duration and activity of the patients are shown in Table 1 . The CD14 ++ CD16 + and CD14 + CD16 + monocytes were assessed in only 12 of the controls while IL17 level was measured in all the controls.
Regarding disease duration
The percentage of CD14 ++ CD16
+ monocytes was significantly higher in long standing compared with early RA patients and controls (p < 0.01, p < 0.001 respectively) ( Table 2 , Fig. 1 ). It was also significantly higher in patients with early RA compared to healthy controls (p < 0.01). The percentage of CD14 + CD16 + monocytes were significantly lower in early RA than healthy controls (p = 0.04). Regarding CD16 + MFIR on CD14 ++ and CD14 + monocytes: there was no significant difference when comparing between the three groups; long standing RA, early RA and controls (Table 2) . IL17 levels were significantly higher in early and long standing RA compared to controls (p < 0.01, p < 0.001 respectively) ( Table 2 ).
Regarding disease activity
+ monocytes was significantly higher in patients with RA disease activity and remission compared with the healthy controls (p < 0.001, p < 0.01 respectively). Comparisons according to the degree of disease activity are presented in Table 2 . A significant difference was present between patients with moderate and high disease activity, (p < 0.05). The CD14
percentage was significantly lower only in RA patients with remission compared with healthy controls (Table 2) . However, the CD16 + MFIR on CD14 + monocytes was significantly higher in RA patients with high disease activity compared with those having low and moderate activity (p < 0.05). The ++ monocytes and serum IL-17 according to the state of disease activity is presented for early RA patients in Fig. 2 and for long standing RA patients in Fig. 3 . Significantly higher levels of IL17 were found in RA patients with disease activity compared to those with disease remission and healthy controls (p < 0.01, p < 0.001 respectively) ( Table 2 ). The level was significantly higher in patients with high disease activity than those with moderate disease activity (p < 0.01) ( Table 2 ). Table 4 ). Significantly higher levels of IL17 were found in RA patients resistant to DMARDs than responding RA patients (p = 0.017) ( Table 3 ).
Discussion
Monocytes are crucial players in the perpetuation of immune responses and joint damage in RA. Kawanaka et al. reported higher frequency of CD16 + monocytes in the peripheral blood of RA patients [23] , but without distinguishing between subpopulations of CD16 + monocytes. The CD14 low monocyte subset has previously been the major focus of attention in RA due to reports of increased numbers in inflammatory diseases [23] [24] [25] [26] and following reports suggested that they are the main producers of TNF in controls [27] . However, in our current study we found no significant difference in the percentage of the CD14 + CD16 + monocyte subset in RA patients between early and long standing disease, or those in activity and remission; and did not correlate with IL 17 levels, disease + monocytes in patients with early RA compared to controls [35] .
In the present study; the percentage of CD14 ++ CD16 + monocytes was not significantly different between patients with disease activity and remission or according to the degree of activity which is consistent with Klimek et al. [35] . However, a significant difference was present between patients with moderate and high disease activity. CD16 + monocytes have been demonstrated to be the main producers of TNF in response to lipopolysaccharides [36] . It has demonstrated that monocytes from RA patients show an enhanced capacity to produce TNF in response to IgG-containing immune complexes and the extent of TNF-production is correlated with the level of CD16 expression on CD14 ++ monocytes [33] . It has been demonstrated that magnetic-bead isolated CD16 + monocytes adhere to activated endothelium and migrate into the joint more efficiently than CD16
À monocytes due to increased adhesion molecule and chemokine receptor expression [37] .
It has been shown that monocytes are important targets for MTX treatment in RA patients [38, 39] [40] .
IL-17 -producing CD4 + T cells have emerged as a major pathogenic T cell population that is present at increased frequencies in RA and correlates with disease severity [41] . The underlying mechanisms of this expansion of the Th17 cell population are not fully understood, but in vivo-activated monocytes from rheumatoid synovium have been shown to be able to drive strong Th17 cell differentiation in vitro [8] , indicating a central role for direct T cell-monocyte contact in this process. In this study, the percentage of CD14 + subpopulation is indeed functionally linked to the observed expansion of the Th17 cell population in RA [34] . In this study, IL17 levels were significantly higher in RA patients than healthy controls, RA patients with disease activity than remission, patients with high activity than those with moderate disease activity, RA patients resistant to DMARD than responding patients which is consistent with previous studies [32, [42] [43] [44] .
Conclusion
We have demonstrated that CD14 ++ CD16 + monocyte subpopulation expanded in long standing than early RA patients and was higher in those with high disease activity indicating its potential pathogenic importance in driving the inflammatory responses in RA. The positive correlation between CD14 ++ CD16 + monocyte percentage and serum level of IL17 indicated that it may have a role in promotion and maintenance of the pathogenetically relevant Th17 cell compartment in RA. Further studies are needed to determine whether monocyte CD16 expression levels could potentially be used as a prognostic or predictive biomarker of response to methotrexate therapy in RA. Furthermore, blockade of CD16 represents an attractive target for future therapeutic intervention.
